GBT stock forecast
Our latest prediction for Global Blood Therapeutics, Inc.'s stock price was made on the April 6, 2017 when the stock price was at 33.35$.
In the short term (2weeks), GBT's stock price should underperform the market by -1.36%. During that period the price should oscillate between -10.99% and +12.33%.
In the medium term (3months), GBT's stock price should outperform the market by 0.42%. During that period the price should oscillate between -22.98% and +32.06%.Get email alerts
About Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -3.90$ per share.
The book value per share is 9.73$
Three months stock forecastApril 6, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|